KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Sales and Divestitures (2016 - 2018)

Biomarin Pharmaceutical's Gains from Sales and Divestitures history spans 8 years, with the latest figure at $963062.0 for Q4 2018.

  • For the quarter ending Q4 2018, Gains from Sales and Divestitures rose 14.93% year-over-year to $963062.0, compared with a TTM value of $963062.0 through Dec 2018, up 14.93%, and an annual FY2018 reading of $963062.0, up 14.93% over the prior year.
  • Gains from Sales and Divestitures for Q4 2018 was $963062.0 at Biomarin Pharmaceutical, up from $837926.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $963062.0 in Q4 2018, with the low at $383332.0 in Q4 2014.
  • Average Gains from Sales and Divestitures over 5 years is $684964.8, with a median of $751203.0 recorded in 2016.
  • Year-over-year, Gains from Sales and Divestitures surged 53.53% in 2016 and then increased 11.54% in 2017.
  • Tracing BMRN's Gains from Sales and Divestitures over 5 years: stood at $383332.0 in 2014, then increased by 27.64% to $489301.0 in 2015, then surged by 53.53% to $751203.0 in 2016, then increased by 11.54% to $837926.0 in 2017, then grew by 14.93% to $963062.0 in 2018.
  • Per Business Quant, the three most recent readings for BMRN's Gains from Sales and Divestitures are $963062.0 (Q4 2018), $837926.0 (Q4 2017), and $751203.0 (Q4 2016).